Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 2/20 | 0.49 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | GSK3B | P49841 | 2/20 | 0.48 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.47 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12568921 | 0.83 | KMT2A (0.54) | KMT2AALDH1A1MEN1BCHEACHE | |
| SCHEMBL28946798 | 0.82 | KMT2A (0.69) | TDP1KMT2AALDH1A1MEN1BCHE | |
| SCHEMBL12572520 | 0.81 | NPC1 (0.62) | KMT2AALDH1A1POLBMEN1GSK3B | |
| SCHEMBL18351270 | 0.81 | KMT2A (0.49) | TDP1KMT2AALDH1A1MEN1BCHE | |
| SCHEMBL2439424 | 0.81 | NPC1 (0.62) | KMT2AALDH1A1POLBMEN1GSK3B | |
| SCHEMBL13912376 | 0.81 | KMT2A (0.68) | TDP1KMT2AALDH1A1MEN1BCHE | |
| SCHEMBL29171625 | 0.81 | NPC1 (0.56) | TDP1HRH3GSK3B | |
| SCHEMBL2443481 | 0.81 | KMT2A (0.68) | TDP1KMT2AALDH1A1MEN1BCHE | |
| SCHEMBL17973365 | 0.80 | KMT2A (0.58) | TDP1KMT2AALDH1A1MEN1BCHE | |
| SCHEMBL8429957 | 0.79 | TDP1 (0.52) | TDP1HRH3KMT2AALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1643989-B1 | CIS-IMIDAZOLINES AS MDM2 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-04-28 | — | — | EP | disclosed |
| EP-1643989-B1 | CIS-IMIDAZOLINES AS MDM2 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-04-28 | — | — | EP | disclosed |
| US-7132421-B2 | CIS-imidazoles | HOFFMANN-LA ROCHE INC. (US) | 2006-11-07 | — | — | US | disclosed |
| EP-1643989-A1 | CIS-IMIDAZOLINES AS MDM2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005002575-A1 | CIS-IMIDAZOLINES AS MDM2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-13 | — | — | WO | disclosed |
| US-20040259867-A1 | CIS-imidazoles | FOTOUHI NADER (US) | 2004-12-23 | — | — | US | disclosed |
| US-20040259867-A1 | CIS-imidazoles | FOTOUHI NADER (US) | 2004-12-23 | — | — | US | disclosed |
| US-20040259867-A1 | CIS-imidazoles | FOTOUHI NADER (US) | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259867-A1 | CIS-imidazoles | TP53, MDM2, TP53BP1 | TDP1 1038/4885HRH3 3435/4885KMT2A 3749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.